INTUIT INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INTUIT INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $18.83B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $16.29B | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $14.37B | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | $12.73B | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | $9.63B | Sep 1, 2023 |
| FY2020 | Jul 31, 2020 | $1.82B | Aug 31, 2020 |
| FY2020 | Apr 30, 2020 | $3.00B | Aug 31, 2020 |
| FY2020 | Jan 31, 2020 | $1.70B | Aug 31, 2020 |
| FY2020 | Oct 31, 2019 | $1.17B | Aug 31, 2020 |
| FY2020 | Jul 31, 2019 | $994.00M | Aug 31, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $18.83B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $16.29B | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $14.37B | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | $12.73B | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | $9.63B | Sep 1, 2023 |
| FY2022 | Jul 31, 2020 | $7.68B | Sep 2, 2022 |
| FY2021 | Jul 31, 2019 | $6.78B | Sep 8, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jul 31, 2017 | $842.00M | Sep 1, 2017 |
| FY2017 | Apr 30, 2017 | $2.54B | Sep 1, 2017 |
| FY2017 | Jan 31, 2017 | $1.02B | Sep 1, 2017 |
| FY2017 | Oct 31, 2016 | $778.00M | Sep 1, 2017 |
| FY2017 | Jul 31, 2016 | $754.00M | Sep 1, 2017 |
| FY2017 | Apr 30, 2016 | $2.30B | Sep 1, 2017 |
| FY2017 | Jan 31, 2016 | $923.00M | Sep 1, 2017 |
| FY2017 | Oct 31, 2015 | $713.00M | Sep 1, 2017 |
| FY2016 | Jul 31, 2015 | $696.00M | Sep 1, 2016 |
| FY2016 | Apr 30, 2015 | $2.14B | Sep 1, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $3.87B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $2.96B | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $2.38B | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | $2.07B | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | $2.06B | Sep 1, 2023 |
| FY2020 | Jul 31, 2020 | $445.00M | Aug 31, 2020 |
| FY2020 | Apr 30, 2020 | $1.08B | Aug 31, 2020 |
| FY2020 | Jan 31, 2020 | $240.00M | Aug 31, 2020 |
| FY2020 | Oct 31, 2019 | $57.00M | Aug 31, 2020 |
| FY2020 | Jul 31, 2019 | ($44.00M) | Aug 31, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $4.92B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $3.63B | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $3.14B | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | $2.57B | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | $2.50B | Sep 1, 2023 |
| FY2020 | Jul 31, 2020 | $483.00M | Aug 31, 2020 |
| FY2020 | Apr 30, 2020 | $1.41B | Aug 31, 2020 |
| FY2020 | Jan 31, 2020 | $270.00M | Aug 31, 2020 |
| FY2020 | Oct 31, 2019 | $10.00M | Aug 31, 2020 |
| FY2020 | Jul 31, 2019 | ($153.00M) | Aug 31, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $2.93B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $2.75B | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $2.54B | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | $2.35B | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | $1.68B | Sep 1, 2023 |
| FY2022 | Jul 31, 2020 | $1.39B | Sep 2, 2022 |
| FY2021 | Jul 31, 2019 | $1.23B | Sep 8, 2021 |
| FY2020 | Jul 31, 2018 | $1.19B | Aug 31, 2020 |
| FY2019 | Jul 31, 2017 | $998.00M | Aug 30, 2019 |
| FY2018 | Jul 31, 2016 | $881.00M | Aug 31, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $6.21B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $4.88B | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $5.05B | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | $3.89B | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | $3.25B | Sep 1, 2023 |
| FY2022 | Jul 31, 2020 | $2.41B | Sep 2, 2022 |
| FY2021 | Jul 31, 2019 | $2.32B | Sep 8, 2021 |
| FY2020 | Jul 31, 2018 | $2.11B | Aug 31, 2020 |
| FY2019 | Jul 31, 2017 | $1.60B | Aug 30, 2019 |
| FY2018 | Jul 31, 2016 | $1.46B | Aug 31, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $84.00M | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $191.00M | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $210.00M | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | $157.00M | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | $53.00M | Sep 1, 2023 |
| FY2022 | Jul 31, 2020 | $59.00M | Sep 2, 2022 |
| FY2021 | Jul 31, 2019 | $76.00M | Sep 8, 2021 |
| FY2020 | Jul 31, 2018 | $38.00M | Aug 31, 2020 |
| FY2019 | Jul 31, 2017 | $102.00M | Aug 30, 2019 |
| FY2018 | Jul 31, 2016 | $416.00M | Aug 31, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $36.96B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $32.13B | Sep 3, 2025 |
| FY2024 | Jul 31, 2023 | $27.78B | Sep 4, 2024 |
| FY2023 | Jul 31, 2022 | $27.73B | Sep 1, 2023 |
| FY2022 | Jul 31, 2021 | $15.52B | Sep 2, 2022 |
| FY2021 | Jul 31, 2020 | $10.93B | Sep 8, 2021 |
| FY2020 | Jul 31, 2019 | $6.28B | Aug 31, 2020 |
| FY2019 | Jul 31, 2018 | $5.13B | Aug 30, 2019 |
| FY2018 | Jul 31, 2017 | $4.07B | Aug 31, 2018 |
| FY2017 | Jul 31, 2016 | $4.25B | Sep 1, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $17.25B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $13.70B | Sep 3, 2025 |
| FY2024 | Jul 31, 2023 | $10.51B | Sep 4, 2024 |
| FY2023 | Jul 31, 2022 | $11.29B | Sep 1, 2023 |
| FY2022 | Jul 31, 2021 | $5.65B | Sep 2, 2022 |
| FY2021 | Jul 31, 2020 | $5.83B | Sep 8, 2021 |
| FY2020 | Jul 31, 2019 | $2.53B | Aug 31, 2020 |
| FY2019 | Jul 31, 2018 | $2.32B | Aug 30, 2019 |
| FY2018 | Jul 31, 2017 | $2.71B | Aug 31, 2018 |
| FY2017 | Jul 31, 2016 | $3.09B | Sep 1, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $19.71B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $18.44B | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $17.27B | Sep 3, 2025 |
| FY2025 | Jul 31, 2022 | $16.44B | Sep 3, 2025 |
| FY2024 | Jul 31, 2021 | $9.87B | Sep 4, 2024 |
| FY2023 | Jul 31, 2020 | $5.11B | Sep 1, 2023 |
| FY2022 | Jul 31, 2019 | $3.75B | Sep 2, 2022 |
| FY2021 | Jul 31, 2018 | $2.82B | Sep 8, 2021 |
| FY2020 | Jul 31, 2017 | $1.70B | Aug 31, 2020 |
| FY2019 | Jul 31, 2016 | $1.49B | Aug 30, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $13.98B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $13.84B | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $13.78B | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | $13.74B | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | $5.61B | Sep 1, 2023 |
| FY2022 | Jul 31, 2020 | $1.65B | Sep 2, 2022 |
| FY2021 | Jul 31, 2019 | $1.66B | Sep 8, 2021 |
| FY2020 | Jul 31, 2018 | $1.61B | Aug 31, 2020 |
| FY2019 | Jul 31, 2017 | $1.30B | Aug 30, 2019 |
| FY2018 | Jul 31, 2016 | $1.28B | Aug 31, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $19.67B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $16.99B | Sep 3, 2025 |
| FY2024 | Jul 31, 2023 | $15.07B | Sep 4, 2024 |
| FY2023 | Jul 31, 2022 | $13.58B | Sep 1, 2023 |
| FY2022 | Jul 31, 2021 | $12.30B | Sep 2, 2022 |
| FY2021 | Jul 31, 2020 | $10.89B | Sep 8, 2021 |
| FY2020 | Jul 31, 2019 | $9.62B | Aug 31, 2020 |
| FY2019 | Jul 31, 2018 | $8.56B | Aug 30, 2019 |
| FY2018 | Jul 31, 2017 | $7.30B | Aug 31, 2018 |
| FY2017 | Jul 31, 2016 | $6.69B | Sep 1, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $2.88B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $3.61B | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | $2.85B | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | $2.80B | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | $2.56B | Sep 1, 2023 |
| FY2022 | Jul 31, 2020 | $6.44B | Sep 2, 2022 |
| FY2021 | Jul 31, 2019 | $2.12B | Sep 8, 2021 |
| FY2020 | Jul 31, 2018 | $1.46B | Aug 31, 2020 |
| FY2019 | Jul 31, 2017 | $529.00M | Aug 30, 2019 |
| FY2018 | Jul 31, 2016 | $638.00M | Aug 31, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $5.97B | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | $6.04B | Sep 3, 2025 |
| FY2024 | Jul 31, 2023 | $6.12B | Sep 4, 2024 |
| FY2023 | Jul 31, 2022 | $6.91B | Sep 1, 2023 |
| FY2022 | Jul 31, 2021 | $2.03B | Sep 2, 2022 |
| FY2020 | Jul 31, 2020 | $2.05B | Aug 31, 2020 |
| FY2019 | Jul 31, 2019 | $386.00M | Aug 30, 2019 |
| FY2019 | Jul 31, 2018 | $388.00M | Aug 30, 2019 |
| FY2018 | Jul 31, 2017 | $438.00M | Aug 31, 2018 |
| FY2017 | Jul 31, 2016 | $488.00M | Sep 1, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 13 | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | 10 | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | 8 | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | 7 | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | 7 | Sep 1, 2023 |
| FY2020 | Jul 31, 2020 | 1 | Aug 31, 2020 |
| FY2020 | Apr 30, 2020 | 4 | Aug 31, 2020 |
| FY2020 | Jan 31, 2020 | 0 | Aug 31, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Aug 31, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Aug 31, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 13 | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | 10 | Sep 3, 2025 |
| FY2025 | Jul 31, 2023 | 8 | Sep 3, 2025 |
| FY2024 | Jul 31, 2022 | 7 | Sep 4, 2024 |
| FY2023 | Jul 31, 2021 | 7 | Sep 1, 2023 |
| FY2020 | Jul 31, 2020 | 1 | Aug 31, 2020 |
| FY2020 | Apr 30, 2020 | 4 | Aug 31, 2020 |
| FY2020 | Jan 31, 2020 | 0 | Aug 31, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Aug 31, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Aug 31, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 279.13M | Sep 3, 2025 |
| FY2025 | Jul 31, 2024 | 280.27M | Sep 3, 2025 |
| FY2024 | Jul 31, 2023 | 280.42M | Sep 4, 2024 |
| FY2023 | Jul 31, 2022 | 281.93M | Sep 1, 2023 |
| FY2022 | Jul 31, 2021 | 273.24M | Sep 2, 2022 |
| FY2021 | Jul 31, 2020 | 261.74M | Sep 8, 2021 |
| FY2020 | Jul 31, 2019 | 260.18M | Aug 31, 2020 |
| FY2019 | Jul 31, 2018 | 258.62M | Aug 30, 2019 |
| FY2018 | Jul 31, 2017 | 255.67M | Aug 31, 2018 |
| FY2017 | Jul 31, 2016 | 257.85M | Sep 1, 2017 |